Affinity-purified polyclonal antibodies against the hBRAG (human B cell RAG-associated gene) protein were generated to characterize hBRAG at the biochemical level. Immunoblotting and immunoprecipitation experiments with these antibody reagents demonstrate that this protein can be expressed in B cells as a membrane-integrated glycoprotein disulfide-linked dimer. However, both glycosylated and unglycosylated isoforms of hBRAG are detectable with these reagents. Additionally, their use in cell surface biotinylation and flow cytometry reveals subcellular hBRAG pools both at cell surface and intracellular locations. Co-immunoprecipitation experiments with hBRAG antisera detected the association of hBRAG with phosphorylated proteins in resting B cells, including the protein tyrosine kinase Hck, which is subsequently dephosphorylated upon B cell receptor (BCR) ligation. Consistent with its cell surface expression and possible link to BCR signaling, experiments in which ␣-hBRAG antibodies were used to generate early activation signals suggest a modest but specific element of tyrosine phosphorylation occurring through a putative hBRAG receptor. Additional experiments also suggest that hBRAG may be involved in positively enhancing BCR ligation-mediated early activation events. Collectively, these results are consistent with a function for hBRAG as a B cell surface signaling receptor molecule. Coupled with the earlier observation that hBRAG expression correlates with early and late B cell-specific RAG expression, we submit that hBRAG may mediate regulatory signals key to B cell development and/or regulation of B cell-specific RAG expression.
In a previous report (1), we developed a differential displaybased screening approach to identify and characterize genes that are associated (either directly or inversely) with human recombination activating gene 1 (RAG1) 1 mRNA expression in the context of the B cell lineage. One of the differential display cDNA products isolated using this molecular approach lead to the molecular cloning of a novel gene we named hBRAG (human B cell RAG-associated gene). In characterizing this gene, we showed that it encodes a type II transmembrane (TM) molecule that is conserved across vertebrate species and, as suggested by transfection analysis, has a potential role in the positive regulation of RAG1 mRNA expression, possibly in a B cell-specific context (2) . Furthermore, hBRAG mRNA was found to be co-expressed with human RAG1 in human B cell lines, and found at highest levels in B cell enriched tissues.
In general, type II TM proteins function as intracellular enzymes involved in biosynthesis and post-translational modification pathways (3) . However, among those with immunological function, there are only two examples of type II TM molecules that function as enzymes, the intracellular invariant chain (reviewed in Ref. 3 ) and the cell surface-expressed BP-1 neutral endopeptidase (reviewed in Ref. 4) . The rest, which include the LY49 lectin family and the TNF receptor family, function exclusively as cell surface signaling molecules. Based on the above type II immune response proteins, there are at least two distinct ways that hBRAG could function in the processes of B cell development and RAG regulation. One way would be indirectly, as an intracellular enzyme or chaperone protein involved in transport, synthesis, or post-translational modification of B cell-specific factors. The other way would be directly, as a B cell signal-transducing molecule. However, hBRAG has no homology to any known protein, making it difficult to ascertain clues as to its modus operandi in the aforementioned functions.
To begin biochemical characterization of this molecule, we have generated antiserum to hBRAG and have characterized their specificities in various contexts. In the present study, we extend structural predictions that hBRAG is a glycosylated, membrane-integral disulfide-linked dimer, which may associate with other phosphorylated proteins in resting, but not BCR cross-linked B cells. We also provide evidence suggesting that hBRAG functions as a cell surface receptor capable of transducing signals alone and, potentially, in conjunction with the BCR. Overall, these data suggest that, like other lymphocyte-specific type II molecules, hBRAG may function in developmental and lineage-specific signaling. Furthermore, like other receptors, including IL-7, CD19, and the BCR, this protein may function as a regulator of RAG expression in B cells via intracellular signaling. Finally, our finding that a large intracellular fraction of hBRAG exists cannot exclude a separate, additional role for hBRAG as an intracellular enzyme or chaperone.
EXPERIMENTAL PROCEDURES
Cell Lines, Human Tissues, and Tissue Culture-The cell line panel used for peptide competition assays included the following human cell lines: REH (pro-B), 697 (pre-B), A8-6P (mature B), HeLa (fibroblast), U937 (pro-monocytic). These have been described in detail previously (2) . All human cell lines (unless otherwise indicated) were cultured in RPMI 1640 media (Wisent, Quebec, Canada) supplemented with 2 mM L-glutamine, 100 units/ml penicillin, 100 g/ml streptomycin, and 15% bovine calf serum (Wisent). Mouse cell lines were supplemented additionally with 50 M 2-ME. All cells for all experiments were incubated at 37°C and 5% CO 2 and harvested in the log growth phase. Tissue protein medleys of human heart, placenta, and bone marrow were obtained from CLONTECH (Palo Alto, CA), human thymus tissue was kindly provided by David Hogg (University of Toronto, Toronto), and peripheral blood lymphocytes were obtained from the Sunnybrook Health Sciences Center. For extracting purified human mature B cells, juvenile tonsils were recovered post tonsillectomy. Tonsillar tissue was homogenized manually and subsequently strained through a 70-m nylon cell strainer (Falcon, Franklin Lakes, NJ). The strained cells in the flow-through were then centrifuged in Ficoll-Paque (Amersham Pharmacia Biotech) density gradient. Isolated lymphocytes were washed in RPMI 1640, and B cells were isolated by negative selection using neuraminidase-treated sheep red blood cells (Cedarlane, Hornby, Ontario) to rosette T lymphocytes as per the manufacturer's protocol. All B cell-enriched preparations were analyzed by flow cytometry for percent B lymphocyte purity based on CD19 ϩ expression. hBRAG Peptide Synthesis, Polyclonal Antibody Production, and Affinity Purification-A peptide (UT952) derived from the most hydrophilic N-terminal region of the cloned hBRAG protein, consisting of residues 82-98, was synthesized by Synpep Corporation (Dublin, CA). The peptide was constructed on a Pharmacia Biolynx automated peptide synthesizer and was purified by reversed-phase high pressure liquid chromatography. For immunizations, 2422 was conjugated to keyhole limpet hematocyanin with gluteraldehyde. Two New Zealand White rabbits were immunized by initial intramuscular injections of 500 g of the peptide-keyhole limpet hematocyanin conjugate emulsified in complete Freund's adjuvant. Rabbits were boosted with three subsequent subcutaneous injections of 250 g of the antigen in incomplete Freund's adjuvant every 2 weeks before cardiac puncture. Rabbits were bled 1 week after each boost for serum collection. For affinity purifications of polyclonal antibodies from serum bleeds, UT952 was conjugated to BSA with gluteraldehyde, and peptide-conjugated affinity chromatography columns were prepared by coupling the BSA-conjugated UT952 peptide to a CNBr-activated Sepharose 4B bead matrix (Amersham Pharmacia Biotech) according to the supplier's instructions. 1.5 ml of sera/column was loaded on the column, and after extensive washing of the columns in 1ϫ TBS, ␣-hBRAG antibody fractions were eluted in elution buffer (Pierce) and stored at 4°C.
Pulse/Steady State Labelings and Immunoprecipitations-For pulse labeling experiments, 1 ϫ 10 7 A8-6P cells were washed in 1ϫ PBS and resuspended in a 10-ml volume of L-methionine-free RPMI medium and incubated with 10 Ci/ml Easytag L-[
35 S]methionine (NEN Life Science Products) for 3 h. Alternatively, for steady state labeling experiments, 1 ϫ 10 7 A8-6P cells were resuspended in 10 ml of normal RPMI medium and incubated with 10 Ci/ml Easytag L-[
35 S]methionine (NEN Life Science Products) for 24 h. Cell pellets were solubilized in 6 ml of radioimmune precipitation assay (RIPA) buffer (1% deoxycholate, 1% Triton X-100, 0.1% SDS, 0.15M NaCl, 1 mM EDTA, and 10 mM Tris-HCl, pH 7.5) supplemented with the contents of a complete protease inhibitor mixture tablet (Roche Molecular Biochemicals). Nuclei, cytoskeletal components, and unlysed cells were removed by centrifugation at 4°C for 10 min at 14,000 ϫ g. For each immunoprecipitation reaction, lysates were precleared before immunoprecipitation by incubating 1 ml of cell lysate with 40 l of a 1:1 suspension of protein A-Sepharose (Amersham Pharmacia Biotech) for 1 h at 4°C. Lysates were then incubated with gentle mixing overnight at 4°C with pre-immune sera, crude terminal antisera, affinity-purified rabbit IgG control, or affinitypurified ␣-hBRAG antibodies (antibody concentrations used are detailed in the figure legends). 20 l of a 1:1 suspension of protein A-Sepharose:1ϫ RIPA buffer was added, and samples were mixed for an additional 2 h at 4°C. Resins were washed twice with 1-ml aliquots of the relevant ice-cold immunoprecipitation buffer, and immunoprecipitates were solubilized in 20 l of 2ϫ electrophoresis sample buffer (New England BioLabs Inc., Beverly, MA) supplemented with 1% 2-ME and 0.042 mM dithiothreitol.
In Vitro Transcription/Translation and Co-translational Processing Studies-Transcription reactions were carried out using 0.5 g of linearized pBluescript 8-3 hBRAG cDNA, the T1 transcription mix (MBI Fermentas Inc., Flamborough, Ontario, Canada), and either T3 or T7 RNA polymerase (Promega) for 1 h at 37°C. The DNA template was removed with 2 units of DNase I for 15 min at 37°C. For subsequent translation reactions, the transcription reaction sample, an amino acid mixture without methionine, and [ 35 S]methionine (NEN Life Science Products) at 1 Ci/l was added to the Flexi reticulocyte lysate translation mix (Promega), all on ice. After incubation at 30°C for 1 h, tRNA was digested with RNase A. Translation reactions were divided into four aliquots, each with a final total volume of 20 l. In particular, translations were performed either alone or in the presence of 1 l (2 units) of canine pancreatic microsomal membranes (MBI Fermentas), with 1 l of microsomes and the N-glycosylation competitive inhibitor peptide Ac-Asn-Tyr-Thr-NH 2 (NYT) at 40 M or with 1 l of microsomes and digestion with 50 units of peptide N-glycosidase F (PNGase F) for 2 h at 37°C subsequent to translation. Membrane integration of the translation products was determined by alkaline extraction of samples (10 l) with 100 l of ice-cold 0.1 M Na 2 CO 3 , pH 11.5, followed by recovery of the stripped microsomes by centrifugation (16,000 ϫ g for 15 min), direct resuspension in 2ϫ electrophoresis sample buffer (New England BioLabs) supplemented with 1% 2-ME and 0.042 mM dithiothreitol, SDS-PAGE analysis, and autoradiography. Alternatively, prior to SDS-PAGE analysis, immunoprecipitations of the above translation reactions were performed with either pre-immune sera or affinity-purified ␣-hBRAG antibodies under the same conditions as described above for steady state and pulse labeling experiments. For cleavage of N-linked oligosaccharide groups in cellular proteins, lysates were solubilized in 1ϫ electrophoresis sample buffer (New England BioLabs), diluted 1:5 in 0.5 M NaH 2 PO 4 (pH 7.5) buffer supplemented with 1% Nonidet P-40, and treated with 100 units of PNGase F at 37°C for 2 h.
Cell Surface Biotinylation Assay-Cells were washed with ice-cold borate buffer (10 mM boric acid, 154 mM NaCl, 7.2 mM KCl, 1.8 mM CaCl 2 , pH 9.0). EZ-Link NHS SS-Biotin (Pierce) at 0.8 mM in borate buffer for 15 min at 0°C was used to biotinylate the surface. The cells were then rinsed in 0.192 M glycine, 25 mM Tris, pH 8.3, solution to quench any unreacted reagent. The cells were then lysed with RIPA buffer (1% deoxycholate, 1% Triton X-100, 0.1% SDS, 0.15M NaCl, 1 mM EDTA, and 10 mM Tris-HCl, pH 7.5). An aliquot of the lysate was saved for Western blotting. ImmunoPure (Pierce) immobilized streptavidin (100 l) was added to the lysate for 1 h at 0°C to bind the biotinylated proteins. The supernatant was removed, and an aliquot was saved for Western blotting. The streptavidin beads were washed three times with RIPA buffer. 1ϫ sample buffer (containing 5% 2-␤-mercaptoethanol (2-ME)) was added to the beads, and the samples were boiled for 30 s to cleave the disulfide bond in the biotinylating reagent and release the captured proteins.
Biotinylation of Antibodies and Intracellular/Surface Flow Cytometry-␣-BRAG affinity-purified, terminal bleed antibodies were biotinylated with D-biotin (Molecular Probes) using the method described previously (3) . For surface staining of BRAG expression on the K562 transfectants, aliquots of 10 6 cells were incubated on ice for 30 min with 10 g of ␣-BRAG-biotin antibodies. Cells were washed twice with cold PBS and incubated on ice for 30 min with 2 g of streptavidin-fluorescein isothiocyanate(Molecular Probes). Cells were washed twice with 4 ml of cold PBS and analyzed using a FACScalibur flow cytometer (Becton Dickinson, San Jose, CA). For intracellular staining, BRAG cells were incubated for 30 min on ice with 1 g of ␣-BRAG-biotin antibodies in 1% BSA, 0.3% saponin (Sigma Aldrich Canada Ltd.)/PBS. Cells were washed twice in 2 ml of 0.1% saponin, PBS and resuspended with 1 g of streptavidin-fluorescein isothiocyanate in 1% BSA, 0.3% Saponin/PBS. Cells were washed twice in 2 ml of 0.1% saponin/PBS, resuspended in 1% BSA/PBS, and analyzed immediately on the FACScalibur.
Cross-linking and Co-immunoprecipitation Assays-2 ϫ 10 7 A8-6P cell aliquots/time point were resuspended at 5 ϫ 10 6 /ml of serum-free RPMI medium in 6-well plates and either left unstimulated or crosslinked with 30 g/ml of a polyclonal affinity-purified goat anti-human F(abЈ) 2 antibody (Tago Inc., Burlingame, CA) at 37°C for either 30 s, 1 min, 3 min, or 5 min. Cells were then washed in 9 ml of cold 1ϫ PBS prior to direct solubilization in 1 ml of 1ϫ sample loading buffer (New England BioLabs) for subsequent SDS-PAGE and immunoblot analysis of whole cell lysate fractions. Alternatively, 8 ϫ 10 7 A8-6P cells unstimulated or cross-linked with 30 g/ml anti-human F(abЈ) 2 for 3 min were prepared for immunoprecipitation with ␣-hBRAG, ␣-Hck, or ␣-Lyn antibodies prior to SDS-PAGE and immunoblot analysis. Finally, for co-ligation studies, 2 ϫ 10 7 A8-6P cells were ligated with various combinations of ␣-hBRAG, ␣-human , or ␣-hBRAG ϩ ␣-human at various concentrations and for various durations (see Fig. 8 legend for details). For competitive blocking of hBRAG-specific cross-linking, hBRAG antibodies were pre-incubated with 10 g/ml UT952 peptide overnight at room temperature. Cells were then solubilized in 4 ml of ice-cold mild (co-immunoprecipitation) lysis buffer comprising 150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 5 mM EGTA, 5 mM NaFl, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, and 1% Nonidet P-40 supplemented with the contents of a complete protease inhibitor mixture tablet (Roche Molecular Biochemicals). Immunoprecipitations were carried out as described above for pulse and steady state labeling experiments. For blocking of antibody F c receptors, an F c ␥III/II receptor blocking antibody directed against human CD16/ CD32 (Metarex Corp.) was preincubated with A8-6P cells at 10 g/ml for 1 h at 37°C prior to cell stimulation with ␣-hBRAG or IgG ϩ ␣-human .
SDS-PAGE-Whole cell lysates were sedimented by centrifugation at 14,000 ϫ g at 4°C for 10 min to remove cellular debris, sheared with a 21.5-gauge needle to eliminate chromosomal DNA, and boiled to denature proteins. Whole cell lysates, immunoprecipitates, or in vitro synthesized proteins were electrophoretically resolved on 10% discontinuous SDS-PAGE Tris-glycine pre-cast minigels (Novex, San Diego, CA) at 100 V for 2 h in Tris-glycine running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) using XCell II™ Mini Cell gel runner (Novex). Protein loads varied in various experiments, but in all cases either cell equivalents or 1 mg of proteins were used, and gels were stained with Commassie Blue. Cell lines and tissue samples were washed in 1ϫ PBS and solubilized in either non-denaturing buffer (2ϫ New England BioLabs electrophoresis sample buffer alone, for runs in denaturing, nonreducing conditions or in reducing buffer (2ϫ New England BioLabs electrophoresis sample buffer supplemented with 1% 2-ME and 0.042 mM dithiothreitol) for runs in denaturing, reducing conditions. In each case, the Benchmark molecular pre-stained standard protein ladder (Life Technologies, Inc.) was run in parallel. Following SDS-PAGE, radiolabeled proteins (from steady state labeling, pulse labeling, and in vitro translation experiments) were directly subjected to autoradiography for 24 -48-h periods.
Immunoblotting Conditions and Primary/Secondary Antibodies Used-Unlabeled proteins were electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Mississauga, Ontario, Canada) using the Xcell II blot module (Novex). The membranes were blocked by incubation in 0.25% gelatin, 10% ethanolamine, and 0.1 M Tris-HCl (pH 9.0) for 2 h at room temperature. The blocked nitrocellulose strips were then incubated with various dilutions of primary antibodies for 2 h at room temperature. The primary antibodies used in immunoblotting include: 4G10, a polyclonal anti-phosphotyrosine antibody (␣-PTyr) kindly provided by Dr. Brian Druker (Oregon Health Sciences University, Portland, OR), monoclonal ␣-Lyn and ␣-Fyn antibodies kindly provided by Dr. Kathy Siminovitch (Samuel Lunenfeld Research Institute, Toronto, Ontario), SC-72, a polyclonal ␣-human Hck antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), 6C8, a monoclonal hamster ␣-human Bcl2 antibody (PharMingen), 386.12, a monoclonal mouse ␣-human CD19 antibody (PharMingen), mouse ␣-actin (Amersham Pharmacia Biotech), pre-immune sera from the above described bleeds, crude antisera to the hBRAG peptide UT952, or affinity-purified ␣-hBRAG antibodies. Concentrations of antibodies used vary in the different experiments and are detailed in the figure legends. To determine specific immunoreactivity of hBRAG antibodies, i.e. detection of peptide-blockable bands, duplicate blots in many experiments were run whereby primary antibodies were preadsorbed with free peptide (at various concentrations indicated in the figure legends) overnight at room temperature. Bound primary antibodies were then detected by incubating membranes with either horseradish peroxidase-conjugated goat ␣-rabbit or goat ␣-mouse IgG (BioRad) at dilutions of 1:10000 and 1:5000, respectively, for 2 h at room temperature. For blotting of immunoprecipitates with antibodies against the human proteins Hck and hBRAG, horseradish peroxidaseconjugated protein A was used as a second-step antibody in immunoblotting to decrease background caused by IgG cross-reactivity. The buffer used for washes and incubations was 0.25% gelatin, 0.05% Nonidet P-40, 0.015 M NaCl, 5 mM EDTA, and 0.05 Tris-HCl (pH 7.5). After thorough washing, Western blots were developed using the Renaissance enhanced chemiluminescence detection system (NEN Life Science Products), and blots were exposed for 5-30 s using BioMax MR autoradiography film (Eastman Kodak, Rochester, NY).
RESULTS
Characterization of hBRAG Antibody Specificity-To begin biochemical characterization of the hBRAG protein, affinitypurified polyclonal antibodies were generated against a hydrophilic N-terminal epitope of the hBRAG protein (see "Experimental Procedures"). Prior to using the ␣-hBRAG antibodies in immunoblotting and immunoprecipitation assays, specific reactivity of the various hBRAG antisera bleeds raised against the hBRAG peptide and the corresponding affinity-purified antibodies were tested in Western blotting on BSA-peptide conjugate membrane strips (data not shown). Peptide competition assays using whole cell lysates from the endogenous hBRAG ϩ line A8-6P were then used to test the binding of crude sera and corresponding affinity purified antibodies from initial bleeds on Western blots (Fig. 1A) . These assays showed that, relative to pre-immune serum controls, these antibodies detect two specific, i.e. peptide-blockable antigens: a ϳ52-kDa major band and a minor ϳ63-kDa band). Based on the size difference of the minor product, we hypothesized that it may represent an inefficiently glycosylated isoform of the hBRAG protein. Using the affinity-purified terminal bleed ␣-hBRAG antibodies, the same ϳ52-and ϳ65-kDa-specific peptide-blockable bands found in A8-6P were also observed in the stable expressing K562 8-3 pCEP4-1 hBRAG transfectant but not in the mocktransfected K562 control (Fig. 1B) .
Identification of hBRAG as a Membrane-integrated, Glycosylated Protein-To determine whether the larger specific band seen in Western blots represent the glycosylated isoform of the hBRAG product, two approaches were taken. First, a cell-free system consisting of a reticulocyte lysate supplemented with microsomal membranes was used to assay the N-glycosylation status of the hBRAG protein in vitro ( Fig. 2A) . We previously demonstrated that the in vitro translated hBRAG protein (without post-translational modifications) is present as a doublet of ϳ55 and 60 kDa, the smaller band possibly due to an alternative downstream translational initiation site in the hBRAG sequence N terminus (2) . A similar doublet in cell-free translations was also seen in the current cell-free translations ( Fig. 2A, lane 3) . N-glycosylation at a single site will produce a uniform increase of about 2.5 kDa in the molecular mass of the protein corresponding to the co-translational attachment of the high mannose oligosaccharide, which only occurs in the microsomal lumen (4). Consistent with the structural prediction of 4 potential N-glycosylation sites in the hBRAG extracellular domain, the in vitro synthesized hBRAG protein was found to shift to an ϳ10-kDa larger species in the presence of microsomal membranes ( Fig. 2A, lane 4) . To further extend the above results, ␣-hBRAG antibodies were used to immunoprecipitate specifically in vitro synthesized hBRAG proteins, either alone or in the presence of microsomes. It was shown that the hBRAG affinity-purified antibodies detect the full-length hBRAG protein doublet expressed after cell-free in vitro translation ( Fig.  2A, lane 7) and also recognize the post-translationally modified in vitro translated membrane fraction protein ( Fig. 2A, lane 8) .
Two independent experiments were performed in parallel to confirm that the shift in mobility was specifically due to Nglycosylation rather than other possible post-translational modifications. We used the N-glycosylation cleavage-specific enzyme, N-glycosidase F, and in addition used a competitive peptide inhibitor of N-glycosylation, the acceptor peptide NYT.
With either the addition of NYT or treatment with N-glycosidase F, the N-glycosylation-mediated shift seen in the presence of microsomes was not observed ( Fig. 2A, lanes 4, 5) . Furthermore, in vitro translated products immunoprecipitated with ␣-hBRAG antibodies also demonstrated a specific loss of the glycosylated hBRAG isoform from the microsomal fraction, either with NYT pre-incubation or with N-glycosidase F posttreatment ( Fig. 2A, lanes 9, 10) . Taken together, the results suggest that hBRAG is a membrane-integrated glycoprotein, as has been predicted based upon the amino acid sequence.
Based on densitometric analysis, the upper (ϳ60 kDa) band of the unglycosylated hBRAG cell-free translated product doublet is 2.1-and 2.4-fold more intense than the bottom (ϳ55 kDa) band prior to the addition of microsomes in whole and immunoprecipitated fractions ( Fig. 2A , lanes 2 and 6, respectively). Upon the addition of microsomes, however, the relative amounts of the upper and lower bands are roughly equivalent ( Fig. 2A, lanes 3 and 7) , but the upper band returns to increased amounts relative to the lower band upon either PNGase F or NYT treatment ( Fig. 2A, lanes 4, 5, 8, and 9) , suggesting that the larger species is selectively glycosylated. It is unlikely that this selective glycosylation is a result of alternative translational initiation codon usage, because the potential alternative translation initiation site with a Kozak-like sequence is ϳ40 amino acids C-terminal to the first site and therefore also encodes a protein with four N-glycosylation sites
FIG. 1. Immunochemical characterization of rabbit polyclonal antiserum.
A, Western blot analysis of rabbit polyclonal antiserum reactivity to membrane strips prepared from endogenous hBRAG ϩ A8-6P cell line lysates. Two specific immunoreactive products (a major ϳ52-kDa product and a minor ϳ63-kDa product; denoted by q) were detected by hBRAG 13th week bleed rabbit polyclonal antisera (lot 2422) raised against the hBRAG N-terminal peptide antigen UT952 or by corresponding affinity-purified ␣-hBRAG antibodies. Products were considered specifically immunoreactive if not found in pre-immune sera and blockable in peptide competition assays, i.e. incubating multiple duplicates of membrane strips with each antibody after overnight pre-incubation with increasing concentrations of competing peptide antigen UT952. Membrane strips were incubated with antibody alone (Ϫ) or with increasing amounts of UT952 (triangles). Lanes are as follows: lane 1, incubation with pre-immune serum at a 1:100 dilution; lanes 2 and 3, incubation with pre-immune serum at a dilution of 1:100 and pre-adsorbed with 100 ng and 10 g of UT952, respectively; lane 4, incubation with crude terminal bleed hBRAG rabbit polyclonal antiserum at a 1:100 dilution; lanes 5-8, incubation with crude hBRAG antiserum at a 1:100 dilution; lane 9, incubation of 1 g/ml affinity purified ␣-hBRAG antibodies alone; and lanes 10 -13, incubation of 1 g/ml affinity-purified ␣-hBRAG antibodies pre-adsorbed with 10 ng, 100 ng, 1 g, and 10 g/ml UT952, respectively. B, Western blot analysis of membrane strips prepared from either untransfected K562 lysates (lanes 1 and 2) or from stable hBRAG transfectant K562 8-3 pCEP4-4 lysates (lanes 3 and 4) . Detection of the specific immunoreactive ϳ52-and 63-kDa bands (q) was by incubation with 1 g/ml affinity-purified ␣-hBRAG antibodies either alone (lanes 1 and 3) or in the presence of pre-adsorbed 10 g/ml of UT952 (lanes 2 and 4) . Note the greater relative intensity of the specific 65-kDa product relative to the 52-kDa product in K562 transfectant compared with that seen in endogenous lysates (panels A and B and Fig. 3 ; see "Results" for details). In both A and B, membrane strips all contain equal protein loads (40 g) and lysates have been run under denaturing, non-reducing SDS-PAGE conditions. in its extracellular region. One possible explanation for this observation is that hBRAG, at least in vitro, may be capable of inserting itself in the membrane in two orientations, either as a type II TM protein or, in the inverted orientation, as a type I, and as such perhaps only in one orientation is it glycosylated. The insertion event itself may depend on the cytoplasmic region and its relative length, such that a shorter cytoplasmic tail may allow improper insertion of the protein as a type I rather than type II TM protein, and the extracellular domain with N-glycosylation sites is now the cytoplasmic domain and will not be accessible to N-glycosylation. In this context, alternative initiation site usage may therefore indirectly determine glycosylation status.
A second test for hBRAG glycosylated and unglycosylated isoforms was to assess directly the glycosylation status of either the endogenous hBRAG or transfected cellular hBRAG protein. This assessment was accomplished by treating the lysates with PNGase F prior to immunoblot analysis with Nterminal-specific ␣-hBRAG antibodies (Fig. 2B) . As expected, the 52-and 63-kDa bands were seen with immunoblot analysis of A8-6P and K562 8-3 pCEP4-4 lysates. A nonspecific band at 50 kDa was seen in all lanes. After PNGase F treatment, the minor, 63-kDa product is selectively lost, and relative to the untreated sample, there is more 52-kDa product in both the endogenously expressing cell line A8-6P and in the hBRAG transfectant K562 8-3 pCEP4-4 ( Fig. 2B, lanes 2 and 6) . The low level of glycosylated hBRAG expression seen in these lanes in Fig. 1, A and B (seen only with longer exposures), and with affinity-purified but not crude antisera, is consistent with the relatively low percentage of glycosylated product (ϳ25% as assessed by densitometric analysis of glycosylated/unglycosylated product ratios) seen in immunoprecipitates of cell-free translations (Fig. 2, lane 7) . There are two possible explanations for this finding: either the actual glycosylation of this protein is not efficient and there may exist a large pool of unglycosylated hBRAG, or alternatively, this particular ␣-hBRAG antibody is inefficient at recognizing a possibly different glycosylated conformation. The latter possibility is consistent with the similar intensity of glycosylated product in ␣-hBRAG immunoprecipitations and whole cell lysates ( Fig.  2A, compare lanes 3 and 7) . Interestingly, relative to peptide competitions with the endogenously expressing hBRAG cell line A8-6P, a higher glycosylated:unglycosylated hBRAG ratio is reproducibly seen in stable hBRAG transfectant K562 8-3 pCEP4-4 lysates, indicating that either the transfected hBRAG is more efficiently recognized by antibody or is more efficiently synthesized by cellular machinery. It is also formally possible that the weak glycosylation form seen in endogenous lysates could be the real antigen, whereas the more ubiquitous 52-kDa antigen is not the unglycosylated antigen but a cross-reacting, more highly abundant protein. However, this latter possibility is not consistent with the in vitro translation data and the shift in size seen after PNGase F treatment of A8-6P and K562 8-3 pCEP4-4 lysates. Nevertheless, the fact that the lower molecular weight hBRAG isoform appears to be differently posttranslationally modified could potentially mean that it serves a different function and/or does not have a motif that is present in the longer protein, which alters its cellular distribution, i.e. intracellular versus cell surface expression. 1-5) or immunoprecipitated with affinitypurified ␣-hBRAG antibodies from terminal bleed antiserum raised against the N-terminal hBRAG peptide prior to SDS-PAGE UT952 (2422; lanes 6 -9) . The open arrow shows the unglycosylated hBRAG doublet product, and the closed arrow shows the ϳ70-kDa glycosylated product (see "Results" for details of relative amounts of glycosylated and unglycosylated products in whole and immunoprecipitated cell-free fractions). Numbers to the left indicate the migration positions of the protein standards. Lane 1 represents a negative control in which no cDNA was added. Translation reactions were carried out without microsomes (lanes 2 and 6), with microsomes only (lanes 3 and 7) , with microsomes and the competitive inhibitor NYT (lanes 4 and 8) , or with microsomes only and digestion with PNGase F after translation (lanes 5 and 9). S, indicates the linearized pBluescript 8-3 hBRAG that was transcribed in vitro, using the T3 promoter, to generate a sense RNA; AS, indicates in vitro transcription of 8-3 hBRAG with the T7 promoter to generate an antisense RNA. B, PNGase F treatment of endogenous hBRAG-expressing A8-6P cellular lysates or transfected/untransfected non-endogenous hBRAG-expressing K562 cellular lysates. Lysates were resolved on SDS-PAGE under reducing conditions as described for Fig. 1 and immunoblotted using affinity-purified N-terminal ␣-hBRAG antibody 2422 at 1:1000 dilutions. The ϩ signs (lanes 2, 4, and 6) represent samples treated with 5000 units of PNGase F for 1 h at 37°C; Ϫ signs (lanes 1, 3, and 5 ) denote untreated samples. The putative glycosylated and unglycosylated isoforms (ϳ65 and 52 kDa, respectively) are shown as open and closed arrows, respectively. Note that consistent with the structural prediction of four N-glycosylation sites, the difference in size between the glycosylated products in lysates and in cell-free translations is ϳ10 kDa.
Analysis of hBRAG Protein Expression in Lymphoid Cell Lines and Tissues and Identification of hBRAG
ing peptide (to assess the specificity of products resolved under both conditions). Nonspecific cross-reactive bands were seen at 50 and 60 kDa in all cell lines. As expected, under reducing conditions, the specific 52-kDa major antigen was expressed in B cell lines but not in the non-lymphoid line HeLa or the myeloid cell line U937 (Fig. 3A) . This band was also lost by the addition of competing peptide (ϩ). Under the particular conditions of this assay and the relatively high background and short exposure times, the glycosylated product was not detected. Nevertheless, under non-reducing conditions, in addition to resolving the single polypeptide hBRAG antigen, a larger disulfide-linked specific molecule of ϳ120 kDa could also be resolved in B cells. Based on its molecular mass, this molecule is not likely to represent an unglycosylated hBRAG homodimer but is probably either a glycosylated hBRAG homodimer or an unglycosylated/glycosylated heterodimer. A predominant ϳ80-kDa band was also seen in the pre-B cell line 697 under reducing conditions, but it is likely not a hBRAG heterodimer because it is not competed out by peptide and more likely represents a 697-specific cross-reacting antigen. In tissues, more nonspecific cross-reactivity, i.e. non-peptide-blockable bands, was seen, but both the highly expressed 52-kDaand the lower-expressed 63-kDa-specific single polypeptide products seen previously under denaturing conditions in immunoblots of B cell line lysates were seen in bone marrow and peripheral blood lymphocytes but not in thymus, heart, or placenta unfractionated tissues. Under non-denaturing conditions, the same specific products were seen in the same tissues, but additional, larger dimer and possibly trimer disulfide-linked molecules of ϳ120, 150, and 180 kDa (representing either hetero/ homo glycosylated hBRAG dimers and/or unglycosylated/glycosylated hBRAG hetero/homotrimers) were also seen.
To extend the above immunoblotting results of gels run under non-denaturing conditions and to compare hBRAG isoforms during biosynthesis (prior to, and after post-translational modification), endogenous hBRAG-expressing A8-6P B cells were either metabolically pulse or steady state-labeled, immunoprecipitated with ␣-hBRAG antibodies, and run under non-reducing conditions (Fig. 4) . As in reduced gel immunoblots, larger bands, likely representing multiple hBRAG higher order isoforms (potential homo-or heterodimers), were seen in both steady state and pulse-labeled A8-6P immunoprecipitates (Fig. 4) . Although the specific product sizes are similar between steady state-labeled immunoprecipitates (Fig. 4B) and whole cell lysate products in Western blot assays (Fig. 3) , they are slightly larger in immunoprecipitations of pulse-labeled cellular proteins (Fig. 4A) . This variation cannot be due to alternative splicing because only one transcript is seen in all of the cell lines assessed (2). However, one possibility is that hBRAG may be a highly unstable protein that is particularly susceptible to proteolysis, such that the antisera are detecting various hBRAG degradation isoforms depending on the conditions of the assay. Overall, the results of these assays are consistent with the structural prediction of hBRAG being expressed in B 1-8) or reducing conditions (lanes 9 -18) . Cells include the human pro-B, pre-B, and mature B cell lines REH, 697, and A8-6P, respectively, the human fibroblast cell line HeLa, and myelocytic human cell line U937. B, Western blot analysis of 1 mg of protein lysates from various unfractionated human tissues resolved by SDS-PAGE under either non-reducing (lanes 1-10) or reducing conditions (lanes 11-20) . In both A and B, after proteins were fractionated by SDS-PAGE, they were transferred to a PVDF membrane, and affinity-purified antibodies from terminal bleeds of crude hBRAG antiserum raised against N-terminal peptide UT952 at a concentration of 1 g/ml either alone (Ϫ) or in the presence of excess (500 g/ml) competing peptide UT952 (ϩ) were used to stain the blots, which was followed by detection with a chemiluminescence detection system. The positions of molecular mass standards (expressed in kilodaltons) are indicated on the left. The positions of the specifically immunoreactive bands that are competed out by N-terminal peptide are indicated by arrows. PBL, peripheral blood lymphocytes. cells at least partly as a disulfide-linked dimer, similar to other lymphocyte-specific cell surface-expressed type II transmembrane receptors.
hBRAG Intracellular and Surface Isoforms-To assess whether hBRAG exists as a cell surface protein and/or as an intracellular protein, we performed cell surface biotinylation assays on the above transfectants and on purified human tonsillar B cells (see "Experimental Procedures," Fig. 5A ). Consistent with the flow cytometry data, both cell surface-expressed and intracellular hBRAG fractions were seen in hBRAG transfectants, whole tonsillar fractions, and purified B cells but not in mock transfectants. In the intracellular fraction, more unglycosylated than glycosylated product was present in endogenously expressing cells, whereas a relatively equivalent level of both isoforms in this pool was seen in the K562 hBRAG transfectants. These results are similar to those seen in cellfree translations and immunoblots of whole cellular lysates (Figs. 1-3) . Interestingly, both the putative unglycosylated and glycosylated products (ϳ52 and 63 kDa, respectively) are seen in the intracellular fraction, but only the larger, glycosylated product is seen in the surface fractions (Fig. 5A) . Furthermore, in all lysates assayed using this assay, a large percentage of the post-translationally modified hBRAG protein is retained intracellularly relative to that expressed on the plasma membrane, a finding that is consistent with the structural prediction of a short hBRAG transmembrane region (2) . Finally, these results show that there is more surface and intracellular product in enriched B cells than in whole tonsil, a result consistent with preferential expression of this product in human B cell lines and tissues (2) . Overall, these results suggest that hBRAG is expressed as both a low but detectable glycosylated population on the cell surface and a larger, intracellular fraction of glycosylated and unglycosylated isoforms.
To extend the results seen by flow cytometry, flow cytometry of K562 cells stably transfected with hBRAG (8-3) cDNA was performed using biotinylated versions of the hBRAG antibodies used in Western blotting and immunoprecipitation assays (Fig.  5B) . To control for specific staining, the same assays were performed in the presence of blocking peptide. Relative to the K562 mock transfectant, positive low level surface and intracellular staining were seen in the K562 hBRAG transfectant. Furthermore, this was specific for hBRAG, as the same shift was not seen in the presence of peptide blocking or when using an irrelevant biotinylated primary IgG (Fig. 5B) .
hBRAG Is Associated with Phosphorylated Proteins in Unstimulated Cells That Are Dissociated and/or Dephosphorylated in Response to BCR Signaling-To determine whether hBRAG is part of a signaling cascade (either as a signaling receptor or intermediate), proteins were immunoprecipitated with hBRAG antibodies under mild conditions and immunoblotted with ␣-phosphotyrosine antibodies. As seen in Fig. 6A , hBRAG was found to be associated with phosphorylated proteins in co-immunoprecipitations of unstimulated A8-6P cells (Fig. 6A, lane 11) . We then examined the possibility that hBRAG may also be functionally associated with BCR signaling by assessing changes in physical interactions with other phosphorylated proteins upon BCR ligation. To do this, proteins from OCI LY8-C3P cells that had been cross-linked with saturating concentrations of polyclonal anti-antibody were immunoprecipitated with ␣-hBRAG antisera under mild conditions and subsequently immunoblotted with anti-phosphotyrosine antibodies. From previous experiments, we have observed optimal tyrosine phosphorylation in whole cell lysates using 10 g/ml F(abЈ) 2 anti-for 3 min (5-7) . Surprisingly, ␣-phosphotyrosine immunoblots of co-immunoprecipitates revealed that a ϳ55-59-kDa protein doublet associated with hBRAG in resting cells may in fact either dissociate from hBRAG or, alternatively, be selectively dephosphorylated in response to BCR ligation (Fig. 6A) . A weaker set of larger products also seems to be associated with hBRAG, which are also either dephosphorylated or disassociated upon BCR ligation, and could possibly represent multimers of the major ϳ55-59-kDa doublet products (Fig. 6A ). This doublet (and the larger, minor products) detected in unstimulated B cells are clearly phosphorylated hBRAG-associated antigens, because they can 3 and 4, respectively) ; or affinity-purified ␣-hBRAG antibodies at a 1:100 dilution with or without excess (500 g/ml) blocking peptide UT952 (lanes 5 and 6, respectively). Lane 1 represents the precleared labeled lysate fraction. For both A and B, the positions of molecular mass standards (expressed in kilodaltons) are indicated on the left, and arrows to the right identify the position of specifically immunoreactive bands. be eliminated specifically with the competing peptide (Fig. 6A,  lane 12) .
Various candidate doublet molecules that are constitutively phosphorylated in B cells in the ϳ55-59-kDa molecular mass range include three B cell protein tyrosine kinases (PTKs) known to be associated with BCR signaling, Fyn, Lyn, and Hck, the latter two existing as doublet isoforms of 56/59 and 53/56 kDa, respectively. To assess the possibility that hBRAG associates with any or a combination of these candidate proteins, antibodies against Lyn, Fyn, and Hck were used in co-immunoprecipitation experiments of the same A8-6P lysates under the same conditions as for the original hBRAG co-immunoprecipitations shown in Fig. 6 . The parallel experiment, co-immunoprecipitation with hBRAG, was also performed, and immunoprecipitates were resolved on SDS-PAGE and immunoblotted with either ␣-phosphotyrosine, ␣-hBRAG and either ␣-Lyn, ␣-Fyn, or ␣-Hck antibodies (Fig. 7) . No association with Lyn (Fig. 7A) or Fyn (data not shown) was detected, but hBRAG demonstrated low level association with Hck (hemopoietic cell kinase) in both ␣-Hck immunoprecipitates immunoblotted with ␣-hBRAG and in ␣-hBRAG immunoprecipitates immunoblotted with ␣-Hck antibodies (Fig. 7B) . Based on the intensity of the associated proteins detected in ␣-phosphotyrosine immunoblots of ␣-hBRAG immunoprecipitates, Hck is probably not the only hBRAG-associated antigen being dephosphorylated or dissociated upon BCR ligation in A8-6P B cells (Fig. 7A) . Also noteworthy is that the Hck fraction associated with hBRAG in resting A8-6P cells is likely dephosphorylated rather than dissociated, because comparable levels of Hck are seen in ␣-Hck immunoblots of ␣-hBRAG immunoprecipitates either in the presence or absence of BCR ligation (Fig. 7B) . This assumes that Hck at least partially corresponds to the species that is selectively dephosphorylated in BCRstimulated hBRAG immunoprecipitates. Finally, it is noteworthy that hBRAG itself is not phosphorylated/dephosphorylated, at least not in the fraction that associates with Hck in ␣-Hck immunoprecipitates. This observation, however, does not rule out that hBRAG is phosphorylated/dephosphorylated as part of the 60-kDa whole cell lysate fraction. Further experiments are underway to examine this possibility.
Cross-linking hBRAG Mediates Intracellular Signaling Alone and in Combination with BCR Ligation-The above data
show that hBRAG may function as a cell surface receptor with signaling capabilities. Although a large portion of the glycosylated and unglycosylated forms of this protein seems to be intracellularly retained, a low level can also be expressed on the cell surface (Fig. 5) . To assess hBRAG signaling potential in the context of the B cell lineage, the putative hBRAG cell surface receptor was ligated with ␣-hBRAG antibodies, and proximal signaling parameters, i.e. phosphorylation patterns 5 and 6, respectively) , or K562 hBRAG transfectants (lanes 7 and 8, respectively) were assessed by immunoblotting using the 2422 affinity-purified ␣-hBRAG antibodies 2422 at a concentration of 1 g/ml (see "Experimental Procedures" for details of cell surface biotinylation assay). The same assay was used to assess cell surface supernatants or intracellular lysates of unfractionated tonsils (lanes 9 and 10, respectively) or purified tonsillar B cells (lanes 11 and 12, respectively). As controls for intracellular and plasma membrane fractionation, bcl2 (lanes 1 and 2) and CD19 protein expression (lanes 3 and 4) from A8-6P fractions were assessed under the same assay conditions. The open and closed arrows show the putative glycosylated and unglycosylated hBRAG products, respectively. The positions of molecular mass standards (expressed in kilodaltons) are indicated in the middle. B, flow cytometry of K562 cells stably transfected with empty vector or with vector containing hBRAG fulllength (8-3) cDNA, using biotinylated affinity-purified ␣-hBRAG antibodies from terminal bleed antiserum raised against the N-terminal hBRAG peptide UT952. As negative and positive controls, antibodies were pre-incubated with specific blocking or irrelevant peptide controls, respectively.
in whole cell lysates, were assessed using an ␣-phosphotyrosine antibody in immunoblots (Fig. 8A) . ␣-hBRAG stimulation at presumably saturating concentrations (10 g/ml) generated a low but detectable tyrosine phosphorylation response relative to unstimulated cells and to the irrelevant rabbit IgG control but one that was much lower than that seen following BCR FIG. 6 . Detection of potential hBRAG-associated phosphorylated proteins in resting but not BCR-ligated A8-6P lysates immunoprecipitated with ␣-hBRAG antibodies. A, anti-phosphotyrosine (␣-P Tyr) Western immunoblots showing the effect of BCR ligation on protein tyrosine phosphorylation in whole cell lysates or ␣-hBRAG-immunoprecipitated lysates prepared from hBRAG ϩ mature B cell line variant A8-6P. Whole cell lysates alone from 2 ϫ 10 7 unstimulated A8-6P cells (0) or from 2 ϫ 10 7 A8-6P cells cross-linked with 30 g/ml F(abЈ)2 anti-for either 30 s, 1 min, 3 min, or 5 min were subjected to SDS-PAGE, transferred to PVDF membranes, and probed with a polyclonal anti-phosphotyrosine antibody. Alternatively, lysates prepared from 2 ϫ 10 7 unstimulated A8-6P cells or A8-6P cells cross-linked with 20 g/ml F(abЈ)2 anti-for 3 min were immunoprecipitated (IP) under mild (co-immunoprecipitating) conditions (i.e. 1% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl, pH 8, 5 mM EDTA, 5 mM EGTA, 5 mM NaFl, 1 mM sodium orthovanadate, 1 mM BSA, and protease inhibitors) with either irrelevant affinity-purified rabbit IgG (rIgG) at 10 g/ml or N-terminal 2422 ␣-hBRAG antibodies affinity-purified from terminal bleeds at 10 g/ml dilutions (␣-hBRAG); they were then subjected to SDS-PAGE, transferred to PVDF membranes, and probed with 1.5 g/ml polyclonal 4G10 anti-phosphotyrosine antibody. The position of the putative major ϳ53/56-kDa hBRAG co-immunoprecipitating doublet species that is dephosphorylated upon BCR stimulation is denoted by an arrow, and the positions of molecular mass standards are indicated in the middle. B, the same Western blots stripped and re-immunoblotted ␣-hBRAG antibodies. The same affinity-purified ␣-hBRAG antibodies used in the immunoprecipitations were used but at a concentration of 1 g/ml. For both A and B, the blots were also probed without lysate (Ϫ) to control for cross-reactivity of the mouse ␣-rabbit second-step horseradish peroxidase-conjugated reagent with the heavy chain IgG band. 200 g/ml irrelevant rabbit IgG alone added to immunoprecipitation buffer was also used as a negative control. To test the specificity of bands under the described co-immunoprecipitating conditions, 10 g/ml competing peptide U-T952 was used (ϩUT952); for comparison, an unstimulated sample without peptide blocking was run adjacently (ϪUT952). The position of the putative major ϳ52-kDa hBRAG unglycosylated species recognized by affinity-purified 2422 is denoted by an arrow. The human IgG heavy chain migrates just below this product. Positions of molecular mass standards (expressed in kilodaltons) are indicated on the left.
FIG. 7.
Co-immunoprecipitation of A8-6P lysates with anti-hBRAG antibodies or antibodies against candidate hBRAG-associated, doublet B cell PTKs Lyn and Hck. Lysates were prepared from 2 ϫ 10 7 A8-6P cells that were unstimulated A8-6P (Ϫ) or crosslinked with 20 g/ml F(abЈ) 2 anti-for 3 min (ϩ). Immunoprecipitation conditions and cell and antibody concentrations used are as detailed in Fig. 6 legend and under "Experimental Procedures." Immunoprecipitates were resolved in duplicate on SDS-PAGE under denaturing conditions, transferred to PVDF membranes, and probed with either ␣-hBRAG N-terminal affinity-purified antibodies or antibodies directed against either the Lyn or Hck PTKs. rIgG, rabit immunoglobulin G.
stimulation. It is difficult to ascertain from these experiments whether the phosphorylation pattern is exactly the same or partially overlapping but distinct from that of BCR ligation (Fig. 8A) . Interestingly, when hBRAG was ligated in combination with BCR, this increased the intensity and the pattern of BCR mediated tyrosine phosphorylation, suggesting that it may positively enhance early activation events through the BCR (Fig. 8A, lanes 8 and 9) . However, ligation of the BCR in combination with the irrelevant IgG control also increased BCR-mediated phosphorylation to almost the same degree as ␣-hBRAG ϩ anti-ligation (Fig. 8A, lane 10) . One possible reason for this effect is that the intact IgGs used in these studies may nonspecifically alter BCR signaling by co-crosslinking of F c ␥RII/III receptors. F c receptor ligation is generally thought to be involved in negative signaling via activation of their ITIM motifs and association with shp1 Src homology 2 domains, resulting in the subsequent dephosphorylation of selected downstream signaling intermediates (8) . In the context of B cells, F c ␥RII ligation has been shown to inhibit several consequences of BCR stimulation, including phosphoinositide hydrolysis, intracellular calcium flux, cellular proliferation, and Ig secretion. However, ligation of F c ␥RII in combination with BCR, i.e. ligation, with intact anti-and its effect on resulting phosphorylation patterns, although not well documented in human mature B cells, appears to produce either similar or more intense overall tyrosine phosphorylation patterns in whole cell lysates of mouse BCR ϩ B cells and B cell lines relative to F(abЈ) 2 anti-cross-linking (reviewed in Ref. 8) .
To test for the contribution of F c -mediated nonspecific effects versus specific hBRAG effects in combination with BCR ligation, these components of hBRAG ligation were blocked by pre-incubation of ␣-hBRAG antibodies either with saturating concentrations of UT952 peptide or with saturating concentrations of blocking antibodies directed against the F c ␥RII/III receptor in A8-6 cells. The results of these experiments suggest that increases in tyrosine phosphorylation in A8-6P cells are at least partially mediated by nonspecific F c -mediated effects, as a decrease in phosphorylation was observed with IgGs or hBRAG ligation in the presence of the F c -blocking antibody (Fig. 8B, lanes 5 and 8, respectively) . However, a substantial component of the ␣-hBRAG ligation effect also appears to be specific, as blocking with UT952 has a significant effect in suppressing the enhanced BCR-mediated phosphorylation pattern. This reduction of phosphorylation signal mediated by the competing peptide is more marked than that mediated by Fc block (Fig. 8B, lane 6) . In addition, the intensity of the phosphorylation pattern mediated by ␣-BCR in combination with ␣-hBRAG is increased relative to that mediated by ␣-BCR in conjunction with irrelevant IgG (Fig. 8B, lane 6) . The differences in signal intensity were not due to loading differences, as demonstrated by re-probing immunoblots with an ␣-actin antibody.
DISCUSSION
As seen in ␣-hBRAG immunoblots of whole cell lysates and ␣-hBRAG immunoprecipitations of de novo synthesized proteins under non-denaturing conditions (Figs. 3 and 4 , respectively), we showed that hBRAG exists as a disulfide-linked, dimeric and possibly trimeric protein. We also showed that hBRAG is glycosylated but that a large unglycosylated pool 3) , hBRAG antibodies alone (affinity-purified from terminal bleed antiserum raised against the N-terminal peptide UT952; lanes 4 -6) , or co-ligated with both (lanes 7-9) . The durations and concentrations of antibody stimulation are indicated in each lane. To control for nonspecific effects, 10 g/ml irrelevant affinity-purified rabbit IgG (rIgG) was also used for co-ligation with 10 mg/ml anti-for 3 min (lane 10). B, relative effect of specific hBRAG co-ligation in enhancing BCR-mediated tyrosine phosphorylation. Whole cell lysates were prepared from A8-6P endogenous hBRAG-expressing mature OCI LY8-C3P variants that were either left unstimulated or stimulated for 3 min with either 0.1 or 10 g/ml ␣-human alone (lanes 2 and 3, respectively), 10 g/ml of both ␣-human and ␣-hBRAG (lanes 4 -6) , or the combination of 10 g/ml ␣-human and the irrelevant IgG control. To test for the relative contribution by F c receptor components, A8-6P cells were preincubated with 10 g/ml blocking antibodies directed against human IgG F c receptors (ϩF c block, lanes 5 and 8, respectively). To test for specificity of the hBRAG-mediated effect, hBRAG antibodies were pre-incubated with 10 g/ml competing peptide UT952 (ϩUT952, lane 6). In both A and B, 2 ϫ 10 7 cell equivalents were fractionated by SDS-PAGE run under denaturing conditions and transferred to a PVDF membrane, and phosphotyrosinecontaining proteins were detected using the 4G10 antibody. Blots were also stripped and re-probed with an ␣-actin antibody to control for loading differences.
also exists in whole cell lysates and cell-free translations (Figs.  2 and 5) . The detection of a highly glycosylated hBRAG isoform with hBRAG antisera is consistent with earlier structural predictions of a TM region with four N-glycosylation sites in the hBRAG extracellular domain. Using cell surface staining and biotinylation assays (Fig. 5) , we have also shown that hBRAG can be expressed at low but detectable levels as a cell surfaceexpressed molecule, a finding consistent with the structural prediction that hBRAG, which lacks an endoplasmic reticulum retention signal, should at least partly leak out to the plasma membrane. Finally, we have demonstrated that hBRAG may function as a signaling receptor and mediates phosphorylation changes after being cross-linked alone or together with BCR cross-linking. Structurally consistent with cell surface-expressed hBRAG also being a signaling receptor is the fact there are various candidate signaling motifs in its 81-amino acid cytoplasmic N terminus; these motifs include the consensus cAMP and protein kinase C phosphorylation sites and palmitylation residues (2) shared by various other signaling receptors and intermediates, such as G protein-linked receptors, G proteins, and Src familly kinases including Src, Blk, Lyn, Yes, Hck, Fyn, and Lck (reviewed in Ref. 9) .
The structural features of hBRAG has revealed many parallels to other type II TM proteins preferentially expressed in lymphoid cells and/or with characterized immunologic function. First, like hBRAG, all of these molecules exist as glycosylated, disulfide-linked, higher order structures as homodimers (BP-1, CD69, CD72, LY49, CD94), heterodimers (CD94/NKG2), or homotrimers (CD23, Fas-L; reviewed in Ref. 10) . Second, with the exception of the invariant chain, all are preferentially expressed on the cell surface and function as signaling receptors with either negative signaling potential, i.e. the C-lectin family, or positive/co-stimulatory potential, i.e. the TNF family, mostly involved in T-T and T-B cell interactions. On the other hand, hBRAG has several structural features distinguishing it from other type II proteins with characterized immunologic roles. First, hBRAG has no overall or domainspecific sequence homology to any of these proteins and is likely not a multigene family member, based on genomic Southern blot analysis (2) . Second, with the exception of the C-lectin receptor family members CD23 and CD72, hBRAG mRNA is preferentially expressed in B cells and at low or undetectable levels in T cells (2) . Third, hBRAG has a shorter TM than the above-mentioned molecules, a property of Golgi-associated integral membrane proteins (reviewed in Ref. 11). The fact that the in vitro translated hBRAG product in the presence of microsomes is efficiently targeted to the Golgi membrane and glycosylated (Fig. 2) and the relatively large fraction of intracellular hBRAG in biotinylation experiments (Fig. 5A ) both reinforce this notion. The invariant chain is the only known type II TM protein with characterized immunologic function that is predominantly retained intracellularly. Its intracellular localization, however, can occur via either its retention or endosomal-targeting signals, neither one of which hBRAG contains in its predicted structure. Like TNF ligands and scavenger receptors, hBRAG has many cysteine-rich regions, but these are not similar enough to constitute a TNF or SRCR (scavenger receptor cysteine-rich) motif. hBRAG is also more extensively glycosylated (at least in vitro) than either TNF or C-lectin receptors (Fig. 2) , which have only one or two Nglycosylation sites/polypeptide monomer (the only exception to this being CD30L).
As an extension to the structural features presented above, several functional features of the cell surface-expressed hBRAG fraction support its role as a signaling receptor in the B cell lineage. First, ␣-hBRAG co-immunoprecipitation results suggest that it and/or various phosphorylated molecules associated with it are selectively dephosphorylated (and/or dissociated) within 1 min post-BCR ligation (Fig. 6) ; this suggests that hBRAG either directly phosphorylates these molecules or associates with molecules that are phosphorylated in response to BCR cross-linking. Second, ␣-hBRAG treatment produces low but detectable increases in tyrosine phosphorylation relative to controls and may also enhance BCR-mediated early activation events (Fig. 8) . Finally, hBRAG may associate with Hck because this Src PTK is expressed predominantly in myeloid and B cell lineages (12, 13) . Although involvement of Hck in myeloid lineage signaling pathways is well characterized, its precise role in the BCR signaling pathway is not well understood. However, evidence for its involvement in this process comes from several observations. For example, upon BCR ligation, Hck can be phosphorylated and activated, demonstrating in vitro kinase activity and phosphorylation of various in vivo BCR signaling intermediates including p120 (Cbl), Bcr-abl, and RAS-GTPase-activating protein (reviewed in Refs. 14 and 15). Additionally, Hck can interact with other BCR or pre-BCR components/signaling intermediates including Ig-␤ and Ig-␣ (via its Src homology 2 domains), Bruton's tyrosine kinase, and the Bcr-abl tyrosine kinase (via its Src Homology 3 domains; Refs. 16 and 17; reviewed in Ref. 18) .
Because hBRAG mRNA expression correlates with B cellspecific expression (2), we hypothesize that hBRAG may mediate potentially important developmental regulatory signals in a B cell-specific signaling pathway. Additionally, based on stable transfection experiments of the hBRAG cDNA, which resulted in RAG1 mRNA levels being increased in a B but not a myeloid cell line (2), we further hypothesize that such a pathway is important for B cell-specific RAG expression. Various signaling molecules have functions in RAG regulation at various stages of B cell development (19) . In particular, hBRAG may be involved in signaling-mediated regulation of RAG expression in earlier B cell differentiation, analogous to pre-BCR, pre-T cell receptor, CD19, and the IL-7 receptor. Some of these receptors, such as CD19, have also been shown to have roles in "negative" as well as positive signaling functions (20) . CD19 can lower the threshold of BCR ligation when co-ligated in conjunction with BCR but, conversely, can render a cell refractive to BCR signaling when pre-ligated alone (21) . In this context, it would be interesting to ascertain whether hBRAG may function in an analogous way to CD19 in the ability to exhibit biphasic signaling responses and may be involved in an ITIM-independent negative signaling pathway. Furthermore, hBRAG, like CD19, may be an example of a molecule that can act both in altering BCR-mediated early activation events and in positively altering RAG expression in human B cell development. Additionally, because hBRAG appears to be enriched in peripheral tissues, it may potentially deliver a signal that re-induces RAG expression and secondary rearrangements, much like signaling through the CD40 co-stimulatory receptor, and the IL-4 or IL-7 receptors in mature germinal center B cells (reviewed in Ref. 19) .
The physical and functional interaction of Hck with c-Abl, and with hBRAG is intriguing in the context of the potential involvement of Hck in signaling pathways regulating RAG expression, because both of these Hck-associated proteins may themselves be involved in RAG regulation (2, 22) . In the former case, temperature-dependent activation of an oncogenic version of c-Abl (v-Abl) in pre-B cell variants can down-regulate RAG mRNAs and therefore, unlike hBRAG, appears to be involved in a negative RAG regulatory pathway (22) . The mature germinal center-derived B cell line A8-6P, used in our co-immunoprecipitation assays, has been shown previously to up-regulate its RAG expression in response to BCR cross-linking, a process that may facilitate its ability to undergo multiple "receptor editing" events in vitro (6) . Therefore, with respect to the association of Hck with hBRAG, hBRAG may indirectly positively regulate RAG expression via differential Hck regulation in response to BCR cross-linking. In this context, ␣-phosphotyrosine immunoblots of Hck immunoprecipitates suggest that Hck phosphorylation is increased upon BCR ligation (Fig.  7B) , a finding that is consistent with a previously report of BCR ligation-mediated increases in Hck phosphorylation (16) . In contrast, the hBRAG-associated Hck fraction is dephosphorylated upon BCR stimulation (Fig. 7B) , suggesting the possible differential, negative regulation of Hck by hBRAG. In this context, the phosphorylation and subsequent activation of Hck has been reported to prevent its association with Bcr-Abl, a related family member of the negative RAG regulator v-Abl (22) . Therefore, one mechanism to explain how hBRAG may mediate a positive effect on RAG expression in response to BCR cross-linking is by facilitating Hck-Abl interactions, resulting in an inactive c-Abl fraction incapable of effecting its negative influence on RAG expression (Fig. 9) . Overall, it is tempting to speculate that Hck may be involved in a positive RAG regulatory pathway, either by association with hBRAG or by dissociation with other proteins such as Bcr-Abl.
hBRAG may also have signaling capabilities independent of a native ligand, since it can up-regulate RAG1 mRNA levels in the context of stable transfection studies in human B cell lines (2) . Therefore, as an extension of the model presented in Fig. 9 , a greater quantity of available hBRAG could theoretically result in a larger pool of dephosphorylated Hck available for association with downstream intermediates such as Abl. An alternative explanation is that hBRAG could be a B cell-specific ligand/counter-receptor for a receptor involved in RAG induction or B cell signaling, either novel or already characterized, such as CD40, IL-7 receptor, or IL-4 receptor. In the context of hBRAG as a possible B cell and/or RAG-specific counter-receptor, it is relevant that almost all TNF family type II TM proteins are counter-receptors for co-stimulatory receptors. Furthermore, a stromal cell counter-receptor has been cloned that delivers a RAG-inducing signal to the human pro-B cell line PA6 (24) . Finally, a third possibility is that we have cloned a dominant "active" form of the putative receptor. This activated form would act much like the activated lck transgene, which can activate T cell signaling independent of T cell receptor signals (25) . In this context, another group has recently cloned a cDNA, KIAA0598 (26) , that is nearly identical to hBRAG with the exception of two key base pair deletions and one base pair addition in the open reading frames, resulting in an open reading frame sequence divergence of 40 and 60 amino acids in the middle and C-terminal end stretches, respectively (27) . One possibility for such differences could be functionally important allelic polymorphisms or mutational differences in the hBRAG or the KIAA0598 proteins.
Although the overall results are consistent with cell surface hBRAG functioning as a signaling receptor in B cell development, it could also serve a similar function as that postulated for the mouse early B cell differentiation marker BP-1/6C3. BP-1 is a type II TM metalloaminopeptidase that may influence the IL-7/IL-7 receptor interaction via modification of an IL-7 receptor N-terminal glutamic acid residue and may also cleave stromal cell regulatory peptide (28) (reviewed in Ref. 29) . Because hBRAG is highly expressed in mature B cells, it could cleave germinal center reaction products that negatively signal RAG down-regulation, including BCR components and antigen-presenting cell or T cell ligands. Although it is not uncommon for membrane proteins to be inefficiently folded and thus trapped in the endoplasmic reticulum, we cannot exclude the possibility that hBRAG has a function in B cell development altogether distinct from its function as a signaling receptor, based on the large hBRAG intracellular fraction (Fig. 5B) . In particular, hBRAG could function indirectly, mechanistically in a fashion analogous to that characterized for the preferentially intracellularly expressed type II TM invariant chain protein, which mediates major histocompatibility group class II trafficking/assembly both as a chaperone and a competitive inhibitor molecule. In this context, hBRAG could confer B cell specificity to otherwise ubiquitously expressed proteins. Finally, it may be of relevance that heparan sulfotransferase, an intracellular type II TM enzyme involved in the acetylation and sulfonation of cell adhesion molecules during their biosynthesis (30, 31) , has several structural features suggesting its evolutionary and possibly functional relationship to hBRAG (2) . Because many Golgi-associated type II TM proteins have a role in post-translational modification (4), intracellular hBRAG may function in post-translationally modifying the ligand binding specificity of a B cell-specific molecule. Such modifications are a requirement for the proper functioning of numerous B cell-specific signaling receptors and intermediates (including CD22) (32) (reviewed in Ref. 18) .
Further experiments, including those on indirect immunofluorescence and molecular characterization of hBRAG-associated proteins, should help to define more precisely the function of various hBRAG protein isoforms in different subcellular locations. Other experiments will have to be conducted to further determine the relationship of hBRAG with the KIAA00598 protein. Additionally, the specificity of hBRAG in inducing tyrosine phosphorylation of downstream proteins will have to be tested more precisely (alone and in conjunction with BCR signaling), including determining the kinetics of these effects in normal human B cells and other BCR ϩ B cell lines with hBRAG monoclonal antibodies and/or F(abЈ) 2 hBRAG polyclonal fragment reagents. Experiments to test the role of hBRAG in B cell development, including targeted disruption of the BRAG mouse homologue, are also currently underway.
